Retinal ciliopathy due to mutation in the RPGR gene

Retinal ciliopathy due to mutation in the RPGR gene (also known as RPGR-related retinal dystrophy or RPGR-associated retinitis pigmentosa) is a group of inherited retinal degenerative conditions caused by mutations in the RPGR (Retinitis Pigmentosa GTPase Regulator) gene located on the X chromosome. The RPGR protein plays a critical role in the function and maintenance of photoreceptor cilia in the retina, which are essential for normal vision. When this protein is dysfunctional, photoreceptor cells progressively degenerate, leading to vision loss. RPGR mutations are the most common cause of X-linked retinitis pigmentosa and can also cause cone dystrophy and cone-rod dystrophy. The disease primarily affects the eyes, with key symptoms including night blindness (nyctalopia), progressive loss of peripheral vision leading to tunnel vision, and eventual decline in central visual acuity. In cone and cone-rod dystrophy phenotypes, patients may first experience decreased central vision, photophobia, and color vision abnormalities. Males are typically more severely affected, while female carriers may show variable degrees of retinal involvement ranging from no symptoms to significant visual impairment. Onset is usually in childhood or adolescence, though the rate of progression and severity can vary considerably even within the same family. Currently, there is no definitive cure for RPGR-related retinal ciliopathy, but management includes regular ophthalmologic monitoring, low-vision aids, and supportive care. Gene therapy approaches targeting the RPGR gene are under active clinical investigation, with several trials showing promising early results. Lumevoq and other gene therapy candidates are being evaluated. Patients may also benefit from genetic counseling to understand inheritance risks and from referral to specialized retinal dystrophy centers for access to emerging therapies.

Common questions about Retinal ciliopathy due to mutation in the RPGR gene